Irritable bowel syndrome: an update on therapeutic modalities.
Irritable bowel syndrome (IBS) is the most common condition that a physician faces in the GI clinic. Of the general population, 10 - 25% suffer from symptoms judged to be IBS. The negative impact of this disease includes not only pain, suffering and direct medical expenses but also significant social and job-related consequences. IBS can be the result of dysfunction in any part of the brain-gut axis: alterations in the CNS caused by psychological or other factors, abnormal gastrointestinal motility, or heightened visceral sensations. Diagnosis is based on either the Manning or Rome-II criteria. Education, reassurance and emotional support are the cornerstones of successful treatment. The mainstays of the current therapeutic approach continue to be: stress management strategies, dietary modification entailing addition of dietary fibre and pharmacotherapy. Pharmacotherapy is still limited to treating symptoms. Newer drugs that modulate motility or drugs that modulate visceral sensation may be useful in selected cases. Psychopharmacological agents are useful in the treatment of IBS, especially in those with psychological co-morbidity. Alternative therapies such as homeopathy, acupuncture, special diets, herbal medication and several forms of psychological treatments and hypnotherapy are sought by many patients and are now being offered by physicians as treatment options, either alone or in conjunction with conventional forms of therapy in patients with refractory symptoms.
Farhadi
A
A
Department of Internal Medicine (Division of Digestive Disease), Pharmacology, Molecular Biophysics and Physiology, Rush University Medical Center, Chicago IL, USA.
Bruninga
K
K
Fields
J
J
Keshavarzian
A
A
D015670:Acupuncture Therapy; D002491:Central Nervous System Agents / Q000627:therapeutic use; D003109:Colonic Diseases, Functional / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D004043:Dietary Fiber / Q000008:administration & dosage; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D008517:Phytotherapy
D002491:Central Nervous System Agents; D004043:Dietary Fiber; D005765:Gastrointestinal Agents